Get the Stockscreener App
1.00
7.41%
-0.08
Pre-market:
1.02
0.02
+2.00%
Tscan Therapeutics Inc stock is traded at $1.00, with a volume of 1.89M.
It is down -7.41% in the last 24 hours and down -8.26% over the past month.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
See More
Previous Close:
$1.08
Open:
$1.09
24h Volume:
1.89M
Relative Volume:
2.50
Market Cap:
$56.75M
Revenue:
$21.05M
Net Income/Loss:
$-89.22M
P/E Ratio:
-0.5587
EPS:
-1.79
Net Cash Flow:
$-64.50M
1W Performance:
-1.96%
1M Performance:
-8.26%
6M Performance:
-44.44%
1Y Performance:
-77.73%
1-Day Range:
$0.91
$1.11
1-Week Range:
$0.91
$1.11
52-Week Range:
$0.91
$4.8496
Tscan Therapeutics Inc Stock (TCRX) Company Profile
Name
Tscan Therapeutics Inc
Sector
Industry
Phone
857-399-9500
Address
830 WINTER STREET, WALTHAM
Compare TCRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TCRX
Tscan Therapeutics Inc
|
1.00 | 61.29M | 21.05M | -89.22M | -64.50M | -1.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.04 | 115.56B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
703.26 | 75.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
430.02 | 60.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
900.76 | 55.48B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
196.55 | 43.51B | 447.02M | -1.18B | -906.14M | -6.1812 |
Tscan Therapeutics Inc Stock (TCRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-14-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-16-24 | Initiated | BTIG Research | Buy |
| May-13-24 | Initiated | Needham | Buy |
| Jun-22-23 | Initiated | Wedbush | Outperform |
Tscan Therapeutics Inc Stock (TCRX) Latest News
Tscan Therapeutics stock holds Neutral rating at BTIG after ASH event - Investing.com UK
TScan Therapeutics : ASH 2025 Virtual KOL Presentation - marketscreener.com
Wall Street analysts’ outlook for Tscan Therapeutics Inc (TCRX) - Setenews
TCRX: TSC-101 shows durable efficacy and safety, with pivotal trial and market expansion set for next year - TradingView
Investor MeetingKey Opinion Leader - marketscreener.com
TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition - Yahoo Finance
How Low Can TScan Therapeutics Stock Really Go? - Trefis
TScan Therapeutics (TCRX) Price Target Increased by 10.53% to 7.14 - Nasdaq
TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Average Rating of "Hold" from Analysts - MarketBeat
Is TScan Therapeutics Stock Built to Withstand a Pullback? - Trefis
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points - The Malaysian Reserve
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points (2025-12-04) - Seeking Alpha
TScan to host KOL event discussing updated ALLOHA trial data By Investing.com - Investing.com Canada
TScan Therapeutics To Provide Update On Phase 1 Trial Of TSC-101 In Heme Malignancies Next Week - Nasdaq
TScan to host KOL event discussing updated ALLOHA trial data - Investing.com
TScan Therapeutics to Host Virtual KOL Event on ALLOHA™ Phase 1 Trial Data and Market Opportunities - Quiver Quantitative
TScan Therapeutics to Host Virtual KOL Event to Discuss - GlobeNewswire
TScan Therapeutics, Inc. (TCRX) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
How TScan Therapeutics Inc. stock reacts to oil pricesJuly 2025 Reactions & Community Driven Trade Alerts - BỘ NỘI VỤ
Is TScan Therapeutics Inc a good long term investmentStock Liquidity Analysis & Free Tools to Find Winning Stocks - earlytimes.in
Is TScan Therapeutics Inc. stock dividend yield sustainableTrade Exit Report & Daily Technical Stock Forecast Reports - BỘ NỘI VỤ
TScan Therapeutics Approves Key Employee Retention Program - TipRanks
TScan Therapeutics ties executive pay to pivotal TSC-101 trial - Stock Titan
American Society of Hematology Meeting - marketscreener.com
Cluey Ltd Launches $4.5 Million Entitlement Offer - The Globe and Mail
Tscan Therapeutics Inc (TCRX) is looking forward to a strong quarter - Setenews
Reversal indicators forming on TScan Therapeutics Inc. stockProfit Target & Consistent Profit Alerts - newser.com
Is TScan Therapeutics Inc. stock positioned well for digital economyTrade Ideas & Daily Oversold Bounce Ideas - newser.com
Applying chart zones and confluence areas to TScan Therapeutics Inc.2025 Pullback Review & Reliable Price Breakout Alerts - newser.com
Is TScan Therapeutics Inc. building a consolidation baseJuly 2025 Closing Moves & Safe Capital Growth Stock Tips - newser.com
How TScan Therapeutics Inc. stock performs in high volatility markets2025 Market Outlook & Expert Curated Trade Setups - newser.com
TScan Therapeutics (NASDAQ:TCRX) Cut to Equal Weight at Morgan Stanley - Defense World
Equities Analysts Issue Forecasts for TCRX FY2025 Earnings - Defense World
Best data tools to analyze TScan Therapeutics Inc. stockJuly 2025 Macro Moves & Daily Growth Stock Tips - newser.com
How TScan Therapeutics Inc. stock reacts to global recession fears2025 Major Catalysts & Growth Oriented Trading Recommendations - newser.com
HC Wainwright Cuts TScan Therapeutics (NASDAQ:TCRX) Price Target to $7.00 - Defense World
Should you wait for a breakout in TScan Therapeutics Inc.Weekly Risk Summary & Scalable Portfolio Growth Methods - newser.com
How TScan Therapeutics Inc. stock performs in rate cut cyclesWeekly Trade Review & Real-Time Stock Movement Alerts - newser.com
Using data filters to optimize entry into TScan Therapeutics Inc.2025 Earnings Impact & Technical Pattern Recognition Alerts - newser.com
Morgan Stanley Downgrades TScan Therapeutics to Equalweight From Overweight - MarketScreener
Morgan Stanley downgrades Tscan Therapeutics stock on delayed trials By Investing.com - Investing.com Canada
Morgan Stanley downgrades Tscan Therapeutics stock on delayed trials - Investing.com India
HC Wainwright & Co. Maintains TScan Therapeutics (TCRX) Buy Recommendation - Nasdaq
Tscan Therapeutics Inc Stock (TCRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.67%
0.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):